HOLOXAN 2000 mg

DRUG3 trials

Sponsors

Institut Bergonie, Oncopole Claudius Regaud

Conditions

Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitonealResectableSoft Tissue Sarcomalimbs and trunk wall undifferentiated pleomorphic sarcomas.non-metastatic soft-tissue sarcoma (STS)

Phase 2

TORNADO : RANDOMIZED PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY PLUS RETIFANLIMAB (INCMGA00012) IN PATIENTS WITH SELECTED RETROPERITONEAL SARCOMAS

Active, not recruitingCTIS2023-509498-21-00

Institut BergonieAdult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

Start: 2022-03-16Target: 66Updated: 2025-09-23

Phase 3

CIRSARC : PHASE III TRIAL INVESTIGATING BENEFIT OF INTENSIFIED PERI-OPERATIVE CHEMOTHERAPY WITHIN HIGH-RISK CINSARC PATIENTS WITH RESECTABLE SOFT-TISSUE SARCOMAS

RecruitingCTIS2023-509489-39-00

Institut Bergonienon-metastatic soft-tissue sarcoma (STS), Resectable

Start: 2019-02-05Target: 351Updated: 2025-12-22

Interest of peri operative CHemotherapy In patients with CINSARC high-risk localized Soft Tissue Sarcoma

RecruitingCTIS2024-515384-62-00

Oncopole Claudius RegaudSoft Tissue Sarcoma

Start: 2020-10-09Target: 600Updated: 2025-12-23